Labat Africa (JSE:LAB) 3-Year EBITDA Growth Rate: 8.90% (As of Nov. 2025)


What is Labat Africa 3-Year EBITDA Growth Rate?

Labat Africa JSE:LAB 3-Year EBITDA Growth Rate is 8.90% as of Nov. 2025. The stock has 5 warning signs investors should review. Among 813 Drug Manufacturers companies, Labat Africa ranks better than 50.31% on this metric.

Labat Africa's EBITDA per Share for the six months ended in Nov. 2025 was R0.08.

During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Labat Africa was 108.00% per year. The lowest was -67.10% per year. And the median was -47.70% per year.

Labat Africa  (JSE:LAB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Labat Africa 3-Year EBITDA Growth Rate Related Terms

JSE:LAB vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labat Africa 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labat Africa's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Labat Africa's 3-Year EBITDA Growth Rate falls into.


Labat Africa 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 8.90% mean?
Labat Africa (JSE:LAB) has a 3-Year EBITDA Growth Rate of 8.90% as of Nov. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #404 out of 813 companies in the Drug Manufacturers industry, placing it in the top 49.7%.
Is Labat Africa's 3-Year EBITDA Growth Rate too high?
Labat Africa's current 3-Year EBITDA Growth Rate is 8.90%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Labat Africa's value of 8.90% is 0% at this industry median. Based on the distribution chart, Labat Africa ranks #404 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Labat Africa's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #404 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Labat Africa in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Labat Africa's value of 8.90% is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current 3-Year EBITDA Growth Rate of 8.90% is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Labat Africa and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current 3-Year EBITDA Growth Rate is 8.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.90% and 0% at the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current 3-Year EBITDA Growth Rate is 8.90% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Labat Africa Business Description

Other Exchanges LAO:Germany
Address 75 Maude StreetSandown, The Leonardo 14th Floor, Sandown, Johannesburg, GT, ZAF, 1709
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.